QUIT — Achieve Life Sciences Share News
0.000.00%
Last trade - 00:00- $746.03m
- $573.64m
Brief: Achieve Life Sciences Reports Financial Results For First Quarter 2023 And Provides Corporate Update
Achieve Life Sciences Inc expected to post a loss of 69 cents a share - Earnings Preview
Achieve Life Sciences up on positive trial data for vaping cessation treatment
Brief: Achieve Life Sciences Announces Positive Phase 2 Orca-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit For Participants Treated With Cytisinicline
Brief: Achieve Life Sciences Announces Refresh To Its Board
Brief: Achieve Life Sciences Says Last Subject Completes Phase 3 ORCA-3 Trial
Brief: Achieve Life Sciences - On March 21, Co Entered Into Amendment To Cooperation Agreement With Dialectic Capital Management, LP and Related Entities
Brief: John Fichthorn Says On March 21, Entered Into Amendment To Cooperation Agreement With Achieve Life Sciences
Brief: Achieve Life Sciences Reports Q4 Loss Per Share $0.83
Achieve Life Sciences Inc reports results for the quarter ended in December - Earnings Summary
Achieve Life Sciences Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Achieve Life Sciences Co Entered Into Cooperation Agreement With Dialectic Capital Management
Brief: Achieve Life Sciences Announces Last Subject Dosed In Phase 2 ORCA-V1 Trial Of Cytisinicline For E-Cigarette Cessation
Brief: Achieve Life Sciences Announces Last Subject Dosed In Phase 3 Orca-3 Trial Of Cytisinicline For Smoking Cessation
Brief: Achieve Life Sciences Announces Last Subject Dosed In Phase 3 Orca-3 Trial Of Cytisinicline For Smoking Cessation
Brief: Achieve Life Sciences Inc Files Prospectus Related To Offering Of Upto 12.3 Mln Shares
Brief: Achieve Life Sciences Announces Patent Granted By Uspto For New Cytisinicline Formulation
Brief: John Fichthorn Reports 19.8% Passive Stake In Achieve Life Sciences As Of Nov 18, 2022- SEC Filing
Brief: Achieve Life Sciences Announces Private Placement Of $18.9 Million